PubMed چکیده/رکورد

Evaluating clinical outcomes of using Undermyfork mobile app with Dexcom G7: Protocol for CGM-Undermyfork randomized controlled trial.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

BACKGROUND: Mobile health apps have the potential to enhance education for glycemic management in individuals with type 2 diabetes (T2D). The growing desire to use diabetes-related mobile applications indicates the industry's broad effort in leveraging technology to improve health outcomes in diabetes patients. However, many available applications still lack evidence-based features, and applications that go through clinical validation often do not include an active control in their studies. The purpose of this in-progress trial is to evaluate the effectiveness of a novel photo-based food diary smartphone app (Undermyfork) that visually connects meals to glucose excursions to promote behavior change. METHODS: This is a randomized, controlled, prospective, parallel-group trial with an active comparator, enrolling N = 90 adults with T2D, elevated HbA1c, and continuous glucose monitoring (CGM) naivety in a real-world community-based health system. Participants complete a run-in/screening period, and if eligible, are randomized into the intervention to use CGM alone (Group 1) or to use the Undermyfork mobile app in addition to CGM (Group 2). The trial will examine comparative effectiveness in improving CGM metrics, HbA1c, and diabetes self-care behaviors over 4 months. DISCUSSION: We hypothesize that Group 2 will have more evident improvements in CGM metrics and HbA1c given Undermyfork's focus on utilizing CGM data to understand meal-related decisions that may allow participants to gain insights into the relationship between their dietary choices and glucose fluctuations throughout the day. This trial may have implications for improved glycemic management, reduced risk of diabetes-related complications, and enhanced well-being for individuals with T2D. CLINICAL TRIAL REGISTRATION: Clinicaltrials.govNCT06501612https://clinicaltrials.gov/study/NCT06501612.

متن کامل اصلی

متن در JumpToDate ذخیره نشده است.

برای بررسی دسترسی کتابخانه‌ای یا خرید، رکورد اصلی را باز کنید.

رفتن به منبع اصلی

کلیدواژه‌ها

Continuous glucose monitoringDiabetes technologyFood loggingMobile health applicationsType 2 diabetes
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Pharmacological strategies for slowing the rise of creatinine and urea nitrogen in diabetic kidney disease: A scoping review.

BACKGROUND: Adolescent diabetic kidney disease (DKD) represents an early-onset microvascular complication characterized by prolonged metabolic exposure and accelerated renal decline. Elevated serum creatinine and blood urea nitrogen (BUN) are key biochemical indicators of impaired renal function. OBJECTIVES: This scoping review aims to systematically map and evaluate pharmacological strategies for slowing the rise of creatinine and BUN…

PubMed2026

Dried Blood Spots for Doping Purpose-Two-Step Protocol for Analysis of Non-Threshold Substances and Anabolic Steroid Esters From One Spot/Pebble.

Analytical performance in anti-doping science continues to evolve through the identification of novel metabolites, improved detection sensitivity, and the use of alternative biological matrices. In recent years, dried blood spots (DBS) have gained increasing attention in doping control due to advantages such as improved analyte stability and simplified, cost-effective sample collection, shipment, and storage. However, DBS sampling is i…

PubMed2026

Hematology and Serum Biochemistry Reference Intervals for Captive-Born Owl Monkeys (Aotus nancymae): Effects of Age and Sex.

BACKGROUND: Owl monkeys (Aotus spp.) are a nocturnal nonhuman primate (NHP) native to central and South America that are used as infectious disease research models for human diseases, such as malaria and human immunodeficiency virus. Natural and infectious diseases may cause alterations in the hematology and serum biochemistry values, which necessitate the availability of reliable reference intervals for healthy animals. METHODS: In th…

PubMed2026

Quantitation of Tucatinib, a Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC-ESI-MS/MS: Application to a Pharmacokinetic Study in Mice.

Tucatinib (Irbinitinib, ARRY-380), a potent oral, selective HER2 kinase inhibitor that the FDA, has approved for the treatment of HER2-positive metastatic breast cancer and colorectal cancer. Tucatinib provides a powerful, targeted therapy for HER2-positive cancers, showing substantial benefits in survival and disease control, especially for patients with difficult-to-treat brain metastases, extending options beyond standard chemothera…